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Abstract
Background: Coronavirus disease 2019 (COVID-19) in solid organ transplant (SOT) patients is
associated with more severe outcomes than non-immunosuppressed hosts. The risk factors for
developing the long COVID in acute COVID remain unknown, and the survival outcomes of
long COVID in SOT patients remain understudied.
Methods: We developed several retrospective cohorts. This project included all patients
identified with acute COVID in the National COVID Collaborative Cohort Registry from July 1,
2020, to June 30, 2022.
Patients with long COVID were compared to those without long COVID in the acute COVID
cohorts. Similarly, we compared the patient demographic with long COVID vs. those without
long-term COVID in the SOT cohort. Univariable and multivariable logistics regression was
used to determine the factors related to the probability of the long COVID in the acute COVID
and SOT cohorts. To investigate the patient survival of long COVID in SOT cohort, Multivariables Cox regression was used to determine the time-to-event outcome of patient survival
(death) after adjusting for another demographic. Results: This study included 6,416,500 acute
COVID patients. 31,744 patients were with long COVID, and 6,384,756 patients were with acute
COVID without long-COVID. The mean (q1, q3) age was 39 [22, 57] years; 55% of patients
were female. In the SOT recipient cohort, 511 patients were identified with long-COVID from
ICD diagnosis and 37,771 patients with acute COVID (mean age 56 [40, 66] years; 41% of
patients are female). In the long COVID SOT, age was most likely between 50-60 years and
white non-Hispanic. Most SOT were kidney transplanted recipients. The Cox regression analysis
revealed many significant factors related to patient survival (death), especially older SOT
patients with a much higher hazard ratio. Conclusion: This study has identified the risk factors
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for developing long COVID more likely in both acute COVID and SOT cohorts. For the SOT
cohort, we also investigated hazard ratios of patient survival based on multivariable Cox models.
We find that older patients in SOT were much more likely to die when long COVID.
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Chapter 1 Introduction
The coronavirus disease 19 (COVID-19) pandemic's impact on solid organ transplantation
recipients has been reflective, from patients with acute Covid, long Covid, acute Covid without
long-term Covid. Since the very first year of the emergence of the novel coronavirus, Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in 2019, several critical questions about
COVID-19 in transplantation have surfaced. Long Covid is a novel syndrome that is broadly
defined by the persistence of physical and/or psychological and cognitive symptoms following a
probable or confirmed SARS-CoV-2 infection, usually 3 months from acute infection and lasting
longer than 2 months, with no probable alternative diagnosis.
While it is evident that people with certain underlying risk factors including high blood
pressure, smoking, diabetes, obesity, and other conditions (Garg et al., 2020) are more likely to
have severe outcomes associated with acute COVID-19. There is no distinct link between these
underlying risk factors and long-term problems in those surviving acute COVID-19. But it is
notable that long-COVID-19 syndrome is not just affecting people who were very ill with the
coronavirus. Some patients who were never severely ill with COVID-19 are experiencing longterm symptoms.
Available evidence suggests that Long COVID is a substantial public health problem with
severe consequences for affected individuals and society at large. Patients commonly report being
emotionally affected by health problems related to Long COVID. In the United States, patients
have reported mild to severe financial impacts related to acute COVID-19 (Chopra et al.,2020;
Arab-Zozani et al.,2020). This concern is underlined by reports that Long COVID patients
experience increased disability related to breathlessness and decreased quality of life (Tabacof et
al., 2020). Understanding the needs of these patients will allow for the development of healthcare,
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rehabilitation, and other resources needed to support their recovery (Menges et al.,2021; Sheehy
et al.,2020). Some data on long COVID-19 outcomes in the population of solid organ transplant
(SOT) patients are available; however, it is undecided if these patients fare better or worse
compared with acute COVID patients.
This data further summarizes immunocompromised patients, such as SOT patients, with a
reported concern for worse outcomes and high mortality (Pereira et al., 2020). In contrast, patients
who undergo transplants with a considerable comorbidity burden of dementia, asthma,
hypertension, heart disease, and diabetes mellitus, among others, have previously been shown to
pose a risk of worse outcomes (Guan et al., 2020). Erstwhile studies on COVID-19 in SOT patients
are limited by sample size and focus on hospitalized patients (Pereira et al., 2020). Therefore, this
study wants to investigate the likelihood of long COVID patients in Acute COVID patients and
SOT and patient survival in SOT cohorts with long COVID.
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Chapter 2 Research question and Data resource
Literature reviews: Long Covid-19 is the common term used to describe signs and symptoms
that last for longer than four weeks after getting COVID-19. It is also referred to as Post Covid19 condition. The World Health Organization (WHO) in 2021 defines Long Covid as follows:
“Post Covid-19 condition occurs in individuals with a history of probable or confirmed SARS
CoV-2 infection, usually three months from the onset of Covid-19 with symptoms and that last for
at least 2 months and cannot be explained by an alternative diagnosis.” The SOT patients with
COVID-19 appear to be at higher risk of severe outcomes based on their chronically
immunosuppressed state and underlying medical comorbidities (Elias et al., 2020; Pereira et al.,
2020; Kates et al., 2020).
Despite the relatively early recognition of this condition, an ICD-10-CM code (U09.9,
“Post COVID-19 condition, unspecified”) was not made available for use in the clinical setting
until October 2021. Moreover, this single code may prove insufficient. Considering the phenotypic
and severity variation seen in Long COVID patients, it is likely that subtypes of Long COVID
exist, and such subtypes may correlate with specific underlying mechanisms that different
interventions should target.
Regardless, the fact remains that there is more naming to be done and a particular need to
define and refine computable phenotypes for Long COVID and its subtypes. As can be seen, by
the widely differing estimates of long COVID prevalence across many studies, a lack of
definitional consistency is affecting the accuracy and reproducibility of otherwise robust research
(Ledford, 2022). Among other advantages, refined definitions will enable us to appropriately
define cohorts for clinical studies, provide more precise treatment and clinical decision support,
and accurately estimate long COVID incidence and prevalence. This is a crucial priority for the
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parent program for this work, the NIH Researching COVID to Enhance Recovery (RECOVER)
Initiative (RECOVER, 2022), which seeks to understand, treat, and prevent PASC through a wide
variety of research modalities, including electronic health record (EHR) and real-world data.
Despite widespread concern about the potential for high prevalence and severity of
COVID‐19 among transplant recipients, data on this population is lacking aside from a few single
patient case reports (Michaels et al., 2020; Guillen et al., 2020; Zhu et al., 2020). SOT patients
with long COVID-19 are particularly unknown due to high prevalence of underlying chronic
kidney disease, diabetes mellitus, hypertension, and calcineurin inhibitor (CNI) use. In a
multicenter study of 482 SOTR with COVID-19, 44% of hospitalized patients developed AKI and
15% required renal replacement therapy (Kates et al., 2020). SOT patients with COVID-19 appear
to be at an even higher risk than the general population based on their exposure to chronic
maintenance immunosuppression and underlying comorbidities (Elias et al., 2020; Pereira et al.,
2020; Kates et al., 2020). In this population, older individuals with COVID-19 have a 28-day case
fatality rate of ~20% (Kates et al., 2020; Hilbrands et al., 2020) compared to a 0.8%–2% risk in
the general population (Pastor-Barriuso et al., 2020). Likewise, the risk of AKI in SOT patients
with COVID-19 is increased at ~50% (Cravedi et al., 2020), with one study demonstrating a need
for renal replacement therapy in 23% and graft loss in 6.3% of kidney transplant recipients (Azzi
et al., 2020).
Most SOT patients have one or several associated risk factors for severe or death COVID19, such as hypertension, cardiovascular disease, and chronic kidney disease (Burra et al., 2020).
Hence, some studies reported that SOT patients had a higher COVID-19-related mortality rate than
non-transplant patients (Caillard et al., 2020; Hadi et al., 2021; Miarons et al., 2021; Rinaldi et al.,
2021; Vinson et al., 2021). Due to the novelty of SARS-CoV-2, there is a paucity of data regarding
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many aspects, including its natural course within immunocompromised hosts, the utility of current
treatment regimens employed in non-transplant individuals for SOT patients, the effect of
immunosuppression on the course of the disease, and much more (Cao, 2020; Guillen et al., 2020).
Even though comorbidities, such as obesity, have been reported as risk factors for severe disease
(Singh, 2020), an immunocompromised state has not yet been proven to have a worse clinical
outcome than SARS-CoV-2 infection. Also, as Vishnevetsky correctly points out, viruses that
belong to the same coronavirus family, such as Middle East Respiratory Syndrome (MERS) and
Severe Acute Respiratory Syndrome Coronavirus 1 (SARS), have not shown an increased risk of
infection or worse outcome in immunocompromised patients (Chan et al., 2003; Parks et al., 2018;
Vishnevetsky & Levy, 2020).
Specific Aims
The overall goal of this project is to synthesize existing evidence on the prevalence as well as
demographics and comorbidities aspects of Long COVID-19 in SOT. Information from this study
could also be used to impact transplant patients with long Covid and acute Covid by identifying
gaps in demographics and clinical characteristics within the study period. Therefore, the
researchers are proposing the following specific aims to be addressed in this project.
Aim 1: This study aimed to describe the frequency of long COVID-19 in acute COVID and SOT
recipients.
Hypothesis: The study hypothesizes that there are risk factors related to the probability of long
COVID in acute COVID and SOT.
Approach: We defined the cohorts presented by assigned groups from the ICD 9/10 diagnosis
code for long COVID during the duration of follow-up for 90 days. The detail statistical methods
will be specified in Chapter 3 methods.
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Aim 2: This study aimed to identify the impact and potential risk factors for the long COVID event
in acute COVID and SOT cohorts.
Furthermore, we want to investigate patient survival for SOT patients when have a long COVID.
Hypothesis: The study hypothesizes that immunosuppressive therapy (IST) already results in
long Covid like symptoms masking potential long Covid among SOT recipients.
Approach: The study compares the health outcome of SOT patients with long COVID and acute
COVID, long COVID with acute COVID without long COVID as well as long term COVID
patients with SOT and acute COVID cohorts. The proposed research is innovative as it is one of
the few studies on COVID-19 in the SOT population in the US. The detail statistical methods will
be presented in Chapter 3 methods.

Significance: Through this research, we are able to further compare the health outcome of long
COVID with acute COVID without long COVID patients in the retrospective acute COVID and
SOT patients’ cohorts and determine the risk factors to developing long COVID to identify
potential interventions. Furthermore, we are able to delineate if early anti-viral therapy lessens
long COVID severity in solid organ transplant patients (Kumar et al., 2018). The study further
evaluates whether or not long COVID affects risk factors for the time-to-event outcome of patient
survival (mortality) among SOT patients while taking into consideration underlying medical
conditions such as obesity, chronic lung disease, congestive heart failure (Kates et al., 2020; Webb
et al., 2020). This will help to identify the frequency of patients who may have recovered from
long COVID and acute COVID after a solid organ transplant, as well as patients who had
experienced long COVID and acute COVID without long COVID. Furthermore, this study
considers SOT patients facing infection, morbidity and mortality from long and acute COVID.
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This study then determines if SOT patients with long COVID and acute COVID will be presented
more often with diabetes, asthma, dementia, malignant cancer, congestive heart failure,
hypertension, peripheral vascular disease, and coronary artery disease.

Data resource: The National COVID Cohort Collaborative (N3C) cohort has provided
impactful insights into COVID-19. The N3C Data Enclave is a secure platform through which
the clinical data provided by contributing members is stored in a harmonized format. The data
itself can only be accessed through a secure cloud portal hosted by NCATS and cannot be
downloaded or removed. The N3C is a health record repository containing the largest, most
representative U.S. cohort of COVID-19 cases and controls to date.
Vinson et al. (2021) compared with COVID− patients, COVID+ SOT recipients were
younger, less likely to be White race, and more likely to have had a kidney transplant than another
organ. The sex-based protection from adverse events for acute COVID-19 were mitigated among
transplant recipients, meaning females with SOT have less relative protection compared with the
non-ISC population (Vinson et al., 2021). They also had greater levels of comorbidity, with a
higher prevalence of hypertension, diabetes, CAD, peripheral vascular disease, and CKD. Despite
the increased risk associated with male sex in the general population, (Pereira et al.,2020; Márquez
et al.,2020) male SOT recipients were not more likely to test positive for COVID-19. Likewise, in
the general population, older age is a risk for SARS-CoV-2 infection (Davis et al.,2020).
However, in the study population, (Vinson et al., 2020) saw the opposite in that SOT
COVID+ recipients were significantly younger than those testing negative. Whether the
association between male sex and older age with COVID-19 diagnosis in the general population
relates to a biologic vulnerability to viral infection or to differences in behaviors and lifestyles
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(potentially more travel and contact patterns in males or older individuals leading to more virus
exposure) that might put these patients at increased risk of acquiring COVID-19 remains to be
seen.
In the 90-d following COVID-19 diagnosis, (Vinson et al., 2020) identify that 42.9% of
SOT recipients required hospitalization, compared with the hospitalization rate for COVID-19 in
the general public which has been shown to be 14% to 46% (Kalyanaraman et al.,2020; Reese et
al.,2021). While systematic review and meta-analysis have yielded sizable COVID+ SOT study
populations, (Kremer et al. 2021) the largest COVID+ SOT cohort study to date includes just over
1000 transplant recipients and focuses on outcomes in SOT recipients with COVID-19, rather than
predictors of testing positive for COVID-19 (Jager et al.,2020). The study conducted by (Vinson
et al.,2021) is the largest to date to explore patient characteristics associated with a diagnosis of
COVID-19 in a national cohort of SOT. This information is valuable in that it may help identify
patients who require a lower threshold for COVID-19 screening and had >10k SOT recipients and
the 2022 had >4k SOT recipients who were vaccinated.
In summary, using the N3C in a cohort of SOT patients diagnosed with long COVID, our
main aim is to compare the health outcome of long COVID with acute COVID without long
COVID as well SOT cohort by long COVID and acute COVID in the study population.
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Chapter 3 Methods
Study design: A retrospective cohort study was conducted using data from the N3C platform. The
N3C platform is a multicenter federated research network in the United States that provides realtime access to de-identified healthcare record data of 16 million patients from the participating
healthcare organizations (Haendel et al., 2020). In the real-time search, the data was collected as
part of routine healthcare and is historical in nature. The data was extracted on June 30, 2022, from
which N3C release, and was analyzed on the platform using (e.g., using Python, SQL, and R in
the platform). The study evaluated pre-existing medical conditions and the research included all
patients with long COVID and acute COVID in SOT, long COVID and acute COVID without
long COVID, acute COVID cohort, long COVID patients, and SOT patients on the N3C platform.
Patients included in this study were diagnosed with long Covid, acute COVID, and SOT patients
between July 1, 2020, and June 30, 2022.
Every patient who had long COVID and acute COVID in transplant, including those with
acute Covid without long COVID, were incorporated in the N3C data enclave platform before
June 30, 2022, a cohort extraction date. As a result of the comparison, data released into the N3C
data enclave after June 30, 2022, are difficult to use for studies requiring a true control arm; after
this date, it was not possible to compare age, gender or race, or differences between long COVID
and acute COVID in transplant, long COVID with acute COVID without long COVID. Because
of this, the research limit to data collected as of June 30, which represents 16 million total patients.
Data elements and measurements
The long COVID and acute COVID patients with transplants, long COVID and acute
COVID without long COVID, acute COVID cohort in long-term COVID patients, and SOT cohort
in long-term COVID patients were determined a priori and included patient demographics, such
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as age, race, sex, type of organ transplant (multiple transplantations, kidney transplantation, liver
transplantation, heart transplantation, lung transplantation, and other/unknown transplantations),
and comorbidities (hypertension, diabetes, asthma, malignant cancer, coronary artery disease
[CAD], congestive heart failure [CHF], peripheral vascular disease (PVD), and obesity [i.e. body
mass index (BMI) > 30 kg/m2 ]). Given large amounts of missingness for BMI (>40%), an
indicator was created for missing BMI and included as an adjustment variable in multivariate
analyses.
Statistical Analyses
We used descriptive statistics including mean (SD) and median (q1 and q3) as appropriate
to report baseline (demographic and clinical) characteristics for all different subgroups, where all
patients were stratified by whether they had long-COVID into each group. Counts and percentages
for demographic and clinical characteristics were used in the study population to describe
categorical variables. The study considered a statistical significance of P value <0.05 when
compared the demographic between different groups. In the analysis, among those tested in the
acute COVID and SOT cohorts, the odds ratio of whether receiving a long COVID event were
determined using univariable and multivariable logistic regressions. Any patient factors are
significantly associated with a long COVID event if their P value of < 0.05. The proportion of
patients experiencing an outcome was determined in the 90 d after being tested for long COVID19 (among Acute COVID and SOT cohorts). Finally, the following co-variables including age
(i.e., < 19, 19–34, 35–49, 50–64, and 65+ years), BMI (i.e., <18.5, 18.5 – 24.5, 25.0 – 29.9, 30+),
sex subgroups (i.e., female and male sex) and transplant type (multiple, kidney, heart, lung, liver)
were in Cox regression models for patient survival outcome in SOT cohort. The results of the Cox
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regression analyses were displayed using hazard ratios (HRs) and 95% confidence intervals (CIs).
P-values lower than 0.05 were considered statistically significant in the statistical models.
National Institute of Health’s N3C Data Utilization Request Approval committee approved
the data utilization request of this project. This retrospective cohort study received Institutional
Review Board (IRB) approval from the University of Nebraska Medical Center (0853-21-EP) and
Johns Hopkins University (IRB00309495). The N3C Data Access Committee approved this study,
which operates under the authority of the National Institutes of Health IRB, with Johns Hopkins
University School of Medicine serving as the central IRB. No informed consent was obtained
because the study used a limited data set. This study followed the Enhancing the Quality and
Transparency of Health Research (EQUATOR) reporting guidelines: Reporting of Studies
Conducted Using Observational Routinely Collected Health Data (RECORD). All statistical
analyses were performed using SQL and R.
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Chapter 4 Model results
Study Population Summary
At the time of long-COVID analysis between July 1, 2020, to June 30, 2022, through the
N3C data enclave platform, millions of long COVID patients were identified. Of the 6,416,500
patients who were identified to have long COVID-19 by the ICD 9/10 diagnosis criteria, 6,384,756
patients were acute COVID without long COVID, and the remaining 31,744 patients were long
COVID patients.
Patient Demographic
The mean age (q1, q3) was 39 (22, 57) years, while 45% of patients were men and 55% of
patients were women for the acute-COVID without long COVID, whereas the mean age was
52(39, 64) years, while 36% were men and 64% were women for long COVID, as shown in Figure
1. This was statistically significant with a p-value <0.001, as in Table 1. The overall comparison
study results of acute COVID without long-COVID and long COVID in the Acute COVID cohort
were shown in Table 1, where we have identified race and ethnicity, transplant type, and
comorbidity to be statistically significant with p-value <0.001. The most common findings on the
overall race and ethnicity, as indicated in Table 1, were 60% White non-Hispanic followed by 13%
Black-African American non-Hispanic, 12% Hispanic or Latino any Race, 2.1% Asian nonHispanic, 0.3% Other non-Hispanic, and 12% unknown were all statistically significant. The most
common transplant type was kidney, followed by liver, heart, and lung were also statistically
significant. The distribution of the percentage of transplant type was also statistically significant.
Similarly, comorbidity in dementia, diabetes, asthma, malignant cancer, coronary artery disease,
peripheral vascular disease, congestive heart failure, and hypertension showed statistically
significant with a p-value <0.001.
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Figure 1. Distribution of sex in Acute COVID and long COVID. Percentage of sex is
significantly difference in Acute COVID and long COVID. There are about 10% more female
patients in long COVID
The White non-Hispanic race was the most common, comprising 60%, followed by Black or
African American non-Hispanic (13%), Hispanic or Latino any Race (12%), Asian non-Hispanic
(2.1%), Other non-Hispanic (0.3) and unknown (12%) for acute COVID without long COVID.
For the long COVID, The White non-Hispanic race was the most common, comprising 63%,
followed by Black or African American non-Hispanic (16%), Hispanic or Latino any Race
(13%), Asian non-Hispanic (2.0%), Other non-Hispanic (0.4%) and unknown (5.5%) in Figure 2.
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Figure 2. Demographic and clinical characteristics of race and ethnicity. Black or African
American non-Hispanic are more likely to have long COVID.
Transplanted organs for acute COVID without long COVID and long COVID included
kidneys in 24,129 (55%) patients, liver in 6,998 (16%) patients, heart transplant in 4,587 (11%)
patients, and lung transplant in 3,068 (7.0%) patients. Among these patients, 6,372,935 had
solitary SOT, while 4,783 patients had multiple transplanted organs.
Comparison of acute COVID without long COVID and long COVID patients showed
several differences (Table 1.). At comorbidities, significant difference between acute COVID
without long COVID and long COVID patients was found for dementia before covid indicator
lower (1.5% vs 2.1%, P value < 0.001) than dementia post covid indicator (0.9% vs 1.8%, P value
< 0.001), malignant cancer before covid indicator was higher (5.0% vs 9.9%, P value < 0.001) than
malignant cancer post covid indicator (3.4% vs 7.8%, P value < 0.001), diabetes before covid
indicator was higher (4.9% vs 12.0%, P value < 0.001) than diabetes post covid indicator (3.5%
vs 12.0%, P value <0.001), congestive heart failure before covid indicator was higher (4.1% vs
10%, P value < 0.001) than congestive heart failure post covid indicator (3.0% vs 12.0%, P < value
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0.001), coronary artery disease before covid indicator was higher ( 5.0% vs 10.0%, P value <
0.001) than coronary artery disease post covid indicator ( 3.3% vs 11.0%, P value< 0.001),
hypertension before covid indicator was higher (22% vs 44%, P value< 0.001) than hypertension
post covid indicator (15% vs 43%, P value < 0.001), peripheral vascular disease before covid
indicator was higher (2.2% vs 5.1%, P value < 0.001) than peripheral vascular disease post covid
indicator (1.4% vs 4.4%, P value < 0.001). As for asthma before covid indicator, acute COVID
without long COVID patients received less frequently than long COVID patients (6.9% vs. 17.0%,
P value < 0.001). All comorbidities, including before and post covid indicators, are statistically
significant with a P value < 0.001.
Table 1: Patient demographics and clinical characteristics among long COVID and acute COVID
Without long COVID
Characteristic variables

Overall

Acute COVID without long
COVID

Long COVID

Gender

<0.001

Male

2872550 (45%)

2861210 (45%)

11340 (36%)

Female

3543950 (55%)

3523546 (55%)

20404 (64%)

39 (22, 57)

39 (22, 57)

52 (39, 64)

<19

1269106 (20%)

1267444 (20%)

1662 (5.2%)

19-34

1503840 (23%)

1499755 (23%)

4085 (13%)

35-49

1334706 (21%)

1326222 (21%)

8484 (27%)

50-64

1279002 (20%)

1268832 (20%)

10170 (32%)

≥ 65

1029846 (16%)

1022503 (16%)

7343 (23%)

<18.5

214595 (3.8%)

214258 (3.8%)

337 (1.3%)

18.5-24.9

541029 (9.5%)

538123 (9.5%)

2906 (11%)

Mean (Q1, Q3) of age

P value

<0.001

BMI Category

25-29.9

<20

<20

<20

≥ 30

1374865 (24%)

1360018 (24%)

14847 (57%)

Missing/Unknown

3560962 (63%)

3552824 (63%)

8138 (31%)

725049

719533

5516

White Non-Hispanic

3878526 (60%)

3858476 (60%)

20050 (63%)

Black or African American Non-Hispanic

834719 (13%)

829734 (13%)

4985 (16%)

Hispanic or Latino any Race

785390 (12%)

781181 (12%)

4209 (13%)

Asian Non-Hispanic

137343 (2.1%)

136718 (2.1%)

625 (2.0%)

Other Non-Hispanic

20456 (0.3%)

20339 (0.3%)

117 (0.4%)

Unknown

760066 (12%)

758308 (12%)

1758 (5.5%)

Unknown
Race Ethnicity

<0.001
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Transplant Type

<0.001

Multiple

4783 (11%)

4671 (11%)

112 (16%)

Kidney

24129 (55%)

23813 (56%)

316 (45%)

Liver

6998 (16%)

6933 (16%)

65 (9.3%)

Lung

3068 (7.0%)

2946 (6.9%)

122 (17%)

Heart

4587 (11%)

4504 (11%)

83 (12%)

6372935

6341889

31046

Dementia before covid indicator

93516 (1.5%)

92852 (1.5%)

664 (2.1%)

<0.001

Dementia post covid indicator

59318 (0.9%)

58744 (0.9%)

574 (1.8%)

<0.001

Asthma before covid indicator

445268 (6.9%)

439770 (6.9%)

5498 (17%)

<0.001

Malignant cancer before covid indicator

322293 (5.0%)

319164 (5.0%)

3129 (9.9%)

<0.001

Malignant cancer post covid indicator

220637 (3.4%)

218161 (3.4%)

2476 (7.8%)

<0.001

Diabetes complicated before covid indicator

315855 (4.9%)

312144 (4.9%)

3711 (12%)

<0.001

Diabetes complicated post covid indicator

230135 (3.6%)

226388 (3.5%)

3747 (12%)

<0.001

Congestive heart failure before covid
indicator

264487 (4.1%)

261211 (4.1%)

3276 (10%)

<0.001

Congestive heart failure post covid indicator

197006 (3.1%)

193116 (3.0%)

3890 (12%)

<0.001

Coronary artery disease before covid
indicator

321043 (5.0%)

317735 (5.0%)

3308 (10%)

<0.001

Coronary artery disease post covid indicator

211673 (3.3%)

208276 (3.3%)

3397 (11%)

<0.001

Hypertension before covid indicator

1388522 (22%)

1374529 (22%)

13993 (44%)

<0.001

Hypertension post covid indicator

959356 (15%)

945853 (15%)

13503 (43%)

<0.001

Peripheral vascular disease before covid
indicator

143177 (2.2%)

141552 (2.2%)

1625 (5.1%)

<0.001

Peripheral vascular disease post covid
indicator

91267 (1.4%)

89884 (1.4%)

1383 (4.4%)

<0.001

Unknown

BMI, body mass index; COVID-19, coronavirus disease 2019; Statistically significant at a P < 0.05; data are percentages unless otherwise
specified.

Comparison of Acute COVID and Long COVID in the SOT cohort
We identified 38,282 SOT patients, with 37,771 patients with acute COVID and 511
having long COVID. The demographic comparison of these groups is shown in Table 2. Acute
COVID patients showed lower median age (56 vs. 60 years, P value< 0.001), but the same BMI
max observed or calculated before covid (31 vs. 31, P value= 0.13), lower BMI max observed or
calculated post covid (29 vs. 30, P value = 0.009) than long COVID patients and less likely to be
a White non-Hispanic race (53% of acute COVID SOT were White versus 57% of long COVID
SOT, P value <0.001). Those who were acute COVID were significantly more likely to be
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kidney transplanted recipients than other organ transplant types (58 % of acute COVID versus
51% of long COVID SOT had a kidney transplant, P value < 0.001) because most patients in
SOT are kidney transplanted recipients. Interestingly, liver transplant recipients had 15% of
acute COVID versus 9.8% of long COVID (P value < 0.001). Conversely, lung (7.0% vs. 13.0%,
P value< 0.001) and heart (10% vs. 13.0%) transplant recipients made up a smaller proportion of
those patients testing for acute COVID than those testing long COVID. Hypertension before and
post covid indicators, diabetes before and post covid indicators, congestive heart failure before
and post covid indicators, CAD before and post COVID indicators, and peripheral vascular
disease before and post covid indicators and were common comorbidities in all SOT but
significantly more common in those who were long COVID. The categorical transplant variables
include kidney transplant (61%), the highest of the transplants, followed by liver transplant
(19%), lung transplant (18%), and heart transplant (16%), as in figure 3.

Transplant Type
70
60

Percentage

50
40
30
20
10
0

kidney transplant

liver transplant

lung transplant

heart transplant

Overall

60

18

12

10

Acute COVID

59

18

13

10

Long COVID

65

19

10

6

Figure 3. Outcome of the acute COVID-19 and long COVID by the Transplant types. It is
interesting to find that lung transplanted recipients are statistically significantly double to have
long COVID.
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All patients for comorbidities reported whether there was a statistical difference based on
P-values. Hypertension, diabetes, coronary artery disease, peripheral vascular disease, and
congestive heart failure were common comorbidities in the SOT cohort but significantly more
common in those who had long COVID and acute COVID. Further analysis in more recent
cohorts can be done through some sensitivity analysis by the inclusion of acute COVID without
long COVID individuals matched by age, sex, and race.
Table 2: Patient Demographic Comparison of long COVID and Acute COVID patients in SOT
cohort.
Characteristic Variables

Overall

Acute COVID

Long COVID

Gender

P value
0.7

Male

22422 (59%)

22127 (59%)

295 (58%)

Female

15860 (41%)

15644 (41%)

216 (42%)

Mean (Q1, Q3) of age

56 (40, 66)

56 (40, 65)

60 (48, 68)

<19

3858 (10%)

3849 (10%)

<20

19-34

3331 (8.7%)

3308 (8.8%)

23 (4.5%)

35-49

7297 (19%)

7190 (19%)

107 (21%)

50-64

13171 (34%)

12989 (34%)

182 (36%)

≥ 65

10625 (28%)

10435 (28%)

190 (37%)

White Non-Hispanic

20484 (54%)

20192 (53%)

292 (57%)

Black or African American Non-Hispanic

8097 (21%)

7969 (21%)

128 (25%)

<0.001

Race Ethnicity

Hispanic or Latino any Race

5606 (15%)

5548 (15%)

58 (11%)

Asian Non-Hispanic

1283 (3.4%)

1274 (3.4%)

<20

Other Non-Hispanic

95 (0.2%)

95 (0.3%)

<20

2717 (7.1%)

2693 (7.1%)

24 (4.7%)

Multiple

3538 (9.2%)

3474 (9.2%)

64 (13%)

Kidney

22191 (58%)

21928 (58%)

263 (51%)

Liver

5847 (15%)

5797 (15%)

50 (9.8%)

Lung

2718 (7.1%)

2651 (7.0%)

67 (13%)

Heart

3988 (10%)

3921 (10%)

67 (13%)

kidney transplant

25233 (66%)

24922 (66%)

311 (61%)

Unknown
Transplant Type

<0.001

0.017

liver transplant

8277 (22%)

8180 (22%)

97 (19%)

0.2

lung transplant

3594 (9.4%)

3502 (9.3%)

92 (18%)

<0.001

heart transplant

4971 (13%)

4889 (13%)

82 (16%)

0.045

Dementia before covid indicator

655 (1.7%)

647 (1.7%)

<20

>0.9

Dementia post covid indicator

409 (1.1%)

400 (1.1%)

<20

0.2

BMI max observed or calculated before covid

31 (27, 36)

31 (27, 36)

31 (27, 36)

0.13
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Unknown
BMI max observed or calculated post covid

10895

10763

132

29 (25, 34)

29 (25, 34)

30 (26, 35)

16163

16014

149

Unknown
BMI Category

0.009

0.2

<18.5

399(1.0%)

397(1.1%)

2(0.4%)

18.5-24.9

3635(9.5%)

3594(9.5%)

41(8.0%)

25.0-29.9

7633(20%)

7525(20%)

108(21%)

≥ 30

15750(41%)

15492(41%)

228(45%)

Missing/Unknown

10895(28%)

10763(28%)

132(26%)

Asthma before covid indicator

3859 (10%)

3799 (10%)

60 (12%)

Malignant cancer before covid indicator

7578 (20%)

7448 (20%)

130 (25%)

0.002

Malignant cancer post covid indicator

4264 (11%)

4181 (11%)

83 (16%)

<0.001

Diabetes complicated before covid indicator

14958 (39%)

14698 (39%)

260 (51%)

<0.001

Diabetes complicated post covid indicator

9427 (25%)

9209 (24%)

218 (43%)

<0.001

Congestive heart failure before covid indicator

11222 (29%)

11026 (29%)

196 (38%)

<0.001

Congestive heart failure post covid indicator

6634 (17%)

6454 (17%)

180 (35%)

<0.001

Coronary artery disease before covid indicator

10593 (28%)

10399 (28%)

194 (38%)

<0.001

Coronary artery disease post covid indicator

5589 (15%)

5427 (14%)

162 (32%)

<0.001

Hypertension before covid indicator

31513 (82%)

31044 (82%)

469 (92%)

<0.001

Hypertension post covid indicator

21632 (57%)

21211 (56%)

421 (82%)

<0.001

Peripheral vascular disease before covid indicator

5856 (15%)

5740 (15%)

116 (23%)

<0.001

Peripheral vascular disease post covid indicator

2826 (7.4%)

2749 (7.3%)

77 (15%)

<0.001

0.2

Note: age at COVID; BMI body mass index; Statistically significant at a P < 0.05; COVID coronavirus disease

In the acute COVID cohort, results of the logistics regression analysis of long-term COVID
in Table 3 with higher odds of mortality were present amongst patients older than 65 years (odds
ratio (OR):1.73, 95% CI: 1.66–1.81), with a BMI of 30+ (OR: 1.24, 95% CI: 1.19–1.29),
hypertension (OR: 1.36, 95% CI: 1.32–1.40), diabetes (OR: 1.09, 95% CI: 1.05–1.14), asthma
(OR:1.85, 95% CI: 1.79–1.91), malignant cancer (OR: 1.12, 95% CI: 1.07–1.16), congestive heart
failure (OR: 1.27, 95% CI: 1.22–1.32), peripheral vascular disease (OR: 1.02, 95% CI: 0.96–1.07),
and dementia (OR: 1.18, 95% CI: 1.08–1.29).
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Results from Statistical Models
Table 3: Odd Ratio (95% CI) of the long COVID outcome from multivariable logistical regression
in the acute COVID cohort.
Variables

Odd Ratio (95% CI)

P value

Gender
Male

Ref.

Female

1.35 (1.32, 1.38)

<0.001

Age Group
19-34

Ref.

<19

0.55 (0.52, 0.58)

<0.001

35-49

2.05 (1.97, 2.13)

<0.001

50-64

2.24(2.16, 2.33)

<0.001

≥ 65

1.73(1.66, 1.81)

<0.001

BMI Category
18.5-24.9

Ref.

<18.5

0.57(0.51, 0.64)

<0.001

25.0-29.9

1.07(1.02, 1.12)

0.005

≥ 30

1.24(1.19, 1.29)

<0.001

Missing/Unknown

0.40(0.38, 0.42)

<0.001

Race Ethnicity
White Non-Hispanic

Ref.

Black or African American Non-Hispanic

1.02(0.99, 1.05)

0.3

Hispanic or Latino any Race

1.18(1.14, 1.22)

<0.001

Asian Non-Hispanic

0.98(0.90, 1.06)

0.6

Other Non-Hispanic

1.42(1.17, 1.69)

<0.001

Unknown

0.59(0.56, 0.62)

<0.001

Hypertension before covid indicator

1.36(1.32, 1.40)

<0.001

Diabetes complicated before covid indicator

1.09(1.05, 1.14)

<0.001

Asthma before covid indicator

1.85(1.79, 1.91)

<0.001

Malignant cancer before covid indicator

1.12(1.07, 1.16)

<0.001

Congestive heart failure before covid indicator

1.27(1.22, 1.32)

<0.001

Peripheral vascular disease before covid indicator

1.02(0.96, 1.07)

0.6

Dementia post covid indicator

1.18(1.08, 1.29)

<0.001

Transplant Type
Non-Transplant

Ref.

Multiple

2.29(1.88, 2.75)

<0.001

Kidney

1.33(1.19, 1.49)

<0.001

Liver

1.04(0.81, 1.32)

0.7

Lung

4.06(3.36, 4.85)

<0.001

Heart

1.72(1.37, 2.13)

<0.001

Abbreviations: CI confidence interval; BMI body mass index; Statistically significant at a P < 0.05
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Results of univariable analysis in the SOT cohort examining predictors of testing longterm COVID are shown in Table 4. Among those tested, older age was associated with testing
(odds ratio [OR] 2.08; 95% CI, 1.36 -3.34 for that > 65 y of age versus those aged 19–34 y)
followed by BMI of 30+ (OR: 1.03, 95% CI: 0.74–1.47), hypertension (OR: 1.44, 95% CI: 1.03–
2.06), diabetes (OR: 1.22, 95% CI: 1.01–1.48), asthma (OR:1.06, 95% CI: 0.80–1.39), malignant
cancer (OR: 1.18, 95% CI: 0.95–1.45), congestive heart failure (OR: 1.09, 95% CI: 0.88 –1.33),
peripheral vascular disease (OR: 1.24, 95% CI: 0.99–1.54), and dementia (OR: 1.30, 95% CI:
0.61–2.40). Male gender was more common in the SOT cohort (P value <0.001), and transplant
recipient long-term COVID patients had a higher mean age (P value <0.001) for 19-34 years, and
the White non-Hispanic race was more common in the long-term COVID at baseline (P value
<0.001). Normal weight, hypertension, diabetes, and congestive heart failure were more common
in transplant recipients (all P < 0.001). When tested, those of non-White Hispanic ethnicity and
recipients of kidney versus other organ transplants were more likely to have a greater test result
than patients with any comorbidity other than liver disease. Among those with the SOT cohort,
hypertension, asthma, and congestive heart failure were each associated with increased odds of
testing for long-term COVID-19. In analysis, age over 65, and liver or lung transplant, were
independently associated with a lower likelihood of testing for long-term COVID-19. In contrast,
the test result was more common in the non-White Hispanic race, those with hypertension,
diabetes, peripheral vascular disease, and congestive heart failure immunosuppressive therapy.

Table 4: Odds Ratio (95% CI) of the long COVID outcome from multivariable logistical regression
in the SOT cohort
Variables

Odd Ratio (95% CI)

P value

Gender
Male

Ref.

Female

1.11 (0.93, 1.33)

24

0.200

Age Group
19-34

Ref.

<19

0.42 (0.18, 0.88)

0.029

35-49

2.06(1.33, 3.33)

0.002

50-64

1.75(1.15, 2.80)

0.013

≥ 65

2.08(1.36, 3.34)

0.001

BMI Category
18.5-24.9

Ref.

<18.5

0.71(0.12, 2.35)

0.6

25.0-29.9

1.10(0.77, 1.60)

0.6

≥ 30

1.03(0.74, 1.47)

0.8

Missing/Unknown

0.88(0.62, 1.27)

0.5

Race Ethnicity
White Non-Hispanic

Ref.

Black or African American Non-Hispanic

1.15(0.92, 1.43)

0.2

Hispanic or Latino any Race

0.96(0.71, 1.27)

0.8

Asian Non-Hispanic

0.64(0.30, 1.18)

0.2

Other Non-Hispanic

0.00(0.00, 0.02)

>0.9

Unknown

0.70(0.45, 1.04)

0.093

Hypertension before covid indicator

1.44(1.03, 2.06)

0.038

Diabetes complicated before covid indicator

1.22(1.01, 1.48)

0.039

Asthma before covid indicator

1.06(0.80, 1.39)

0.7

Malignant cancer before covid indicator

1.18(0.80, 1.39)

0.12

Congestive heart failure before covid indicator

1.09(0.88, 1.33)

0.4

Peripheral vascular disease before covid indicator

1.24(0.99, 1.54)

0.062

Dementia post covid indicator

1.30(0.61, 2.40)

0.4

Transplant Type
Kidney

Ref.

Multiple

1.48(1.11, 1.94)

0.007

Liver

0.83(0.60, 1.12)

0.2

Lung

2.24(1.68, 2.96)

<0.001

Heart

1.43(1.06, 1.90)

0.018

Abbreviations: CI confidence interval.; BMI body mass index; Statistically significant at a P value < 0.05

The results of patient survival from the Cox regression models were shown in Table 5. Female
were likely to have a death with Hazard Ratio (HR) = 0.69, (95% CI: 0.68–0.70) while adjusting
for Male patients. HR of age categories were ranged from 2.74 (95% CI: 2.57–2.92) in patients
with aged < 19 years to 27.8 (95% CI: 26.3–29.4) in those elder patients with aged more than 65
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years old. It is very dangerous for elder patients to have a long COVID in SOT because hazard
ratio was so high with 27.8 (26.3, 29.4). It is very interesting to find that overweight and obesity
is beneficial for patient survival in BMI categories.
Table 5: Hazard Ratio of the time-to-event outcome of patient survival from multivariable Cox
models in the SOT cohort with long COVID.
Variables

Hazard Ratio (95% CI)

P value

Gender
Male

Ref.

Female

0.69(0.68, 0.70)

<0.001

Age Group
19-34

Ref.

<19

2.74(2.57, 2.92)

<0.001

35-49

3.16(2.97, 3.36)

<0.001

50-64

9.19(8.69, 9.72)

<0.001

≥ 65

27.8(26.3, 29.4)

<0.001

BMI Category
18.5-24.9

Ref.

<18.5

0.94(0.88, 1.00)

0.037

25.0-29.9

0.80(0.78, 0.83)

<0.001

≥ 30

0.81(0.79, 0.83)

<0.001

Missing/Unknown

0.61(0.59, 0.63)

<0.001

Race Ethnicity
White Non-Hispanic

Ref.

Black or African American Non-Hispanic

1.13(1.11, 1.16)

<0.001

Hispanic or Latino any Race

1.11(1.08, 1.15)

<0.001

Asian Non-Hispanic

1.28(1.21, 1.35)

<0.001

Other Non-Hispanic

0.44(0.33, 0.57)

<0.001

Unknown

1.03(1.01, 1.06)

0.019

Hypertension covid indicator

1.57(1.54, 1.60)

<0.001

Diabetes complicated covid indicator

1.34(1.31, 1.37)

<0.001

Asthma covid indicator

0.71(0.69, 0.73)

<0.001

Malignant cancer covid indicator

1.51(1.48, 1.54)

<0.001

Congestive heart failure covid indicator

2.69(2.64, 2.74)

<0.001

Peripheral vascular disease covid indicator

1.16(1.13, 1.18)

<0.001

Dementia covid indicator

1.15(1.11, 1.19)

<0.001

Transplant Type
Non-Transplant

Ref.

Multiple

1.19(1.05, 1.35)

0.006

Kidney

1.87(1.78, 1.97)

<0.001
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Liver

1.63(1.47, 1.81)

<0.001

Lung

2.05(1.80, 2.32)

<0.001

Heart

0.91(0.80, 1.03)

0.14

Long covid flag

0.47(0.42, 0.52)

<0.001

Abbreviations: HR hazard ratio; BMI body mass index; Statistically significant at a P-Value < 0.05
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Chapter 5 Discussion and conclusion
This study is one of the first comprehensive analyses of long COVID in patients enrolled
in the N3C data enclave platform in those with acute COVID and the SOT transplant groups. We
have identified a SOT cohort of 31,744 with either acute COVID or long COVID. The
comorbidity levels are greater in elderly adults and over, with a higher prevalence of
hypertension, diabetes, coronary artery disease, malignant cancer, congestive heart failure,
peripheral vascular disease, asthma, and dementia. We found that long COVID increased patient
survival risk with male than female male SOT patients, although it was not likely to have
COVID (Vinson et al., 2020). The association between males and older age with long COVID
diagnosis in the overall population relates to a biological vulnerability to viral infection or to
differences in behaviors and lifestyles that might put these male and older patients at increased
risk of acquiring COVID-19 remains to be seen (Vinson et al., 2020). Hence, there may be
speculation that older male SOT patients are not at increased risk for acquiring long COVID-19
because of better adherence to physical distancing and using personal protective equipment (like
N-95 mask, hand sanitizer, Etc.), thereby mitigating any behavioral differences observed in the
overall population.
The present study adds to this literature by showing that long-term COVID is positively
and significantly associated with transplants even after adjusting for potential confounding
factors. Interestingly, this association was further found to be significant in all age and sex
subgroups and BMI categories. Moreover, HRs increased with increasing age, suggesting that
the deleterious effects of this long-term COVID on comorbidities may be stronger in older adults
than in their younger counterparts. The limitations of our study include its retrospective design
and the biases inherent to studies conducted on the N3C data enclave platform. We were able to
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analyze a large sample and control for possible confounders that should strengthen the validity of
our findings. As our data are derived primarily from large academic centers in the United States,
generalizability to other specific populations may be limited. Furthermore, patients with an
asymptomatic course of infection for a long COVID diagnosis based on past covid and a series
of symptoms remain uncaptured in our study. Thus, it can be inferred that our analysis includes a
relatively more “severe” part of the disease spectrum.
In conclusion, we have identified the risk factors to be more likely to develop long
COVID in both acute COVID and SOT cohorts. Importantly, we have investigated hazard ratios
of patient survival based on multivariable Cox models. We find that elderly patients in SOT were
much more likely to die when long COVID. The study underlines patient survival in managing
SOT patients with long COVID. Careful assessment seems important for recognizing patients at
risk of a complicated course. Finally, future research should investigate the potential mediating
factors involved in the relationship between long COVID and transplant centers, such as cluster
statistical models.
Ethical considerations
The only ethical issues that were required to be addressed were managed through the IRB
application for the long COVID transplantation program. The IRB provides oversight, including
ethical oversight, for all research involving humans or human biological material (HBM) at
UNMC. Hence, the study protocol was approved by the UNMC Institutional Review Board
followed by the N3C Data Access and Ethics Committee before analysis. National Institute of
Health’s N3C Data Utilization Request Approval committee approved the data utilization request
of this project. NCATS reviewed all data elements before extraction.
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Application of Public Health Competencies
The above project has uncovered me to a vast majority of public health competencies. The
main foundational competency that this project focuses on is MPHF3: Analyze quantitative and
qualitative data using biostatistics, informatics, computer-based programming and software, as
appropriate. The thorough use of computer programming and biostatistics is at the fore front of
this capstone project. Compilation of data as well as analyzing descriptive statistics are the basics
of this project. All of these were conducted using computer programming software like SQL and
R in the N3C data enclave platform.
The two concentration competencies that are more representative of this project include
BIOSMPH2 and BIOSMPH4. BIOSMPH2 is the application of appropriate statistical methods for
estimation and inference using a software package for data management, statistical analyses, and
data presentation. Hence, the capstone project satisfies this competency through the application of
appropriate statistical methods using SQL and R coding language software. BIOSMPH4 is the
development of written and oral presentations based on the statistical findings for both public
health professionals and lay audiences. The entire information for this project is obtained from the
N3C data enclave platform through the National Institute of Health. Hence, it helps put
presentation slides together that explain the capstone topic of the risk factors of long COVID in
the acute COVID and solid organ transplant retrospective cohorts, emphasizing the specifics,
including tables to professionals and lay audiences.
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